Healthy CD4(+) T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia

An attractive molecular target for novel anti-cancer therapies is the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway which is commonly deregulated in many types of cancer. Nevertheless, the effects of PI3K/Akt/mTOR inhibitors on T lymphocytes, a key component o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Alameen, Ayman A.M., Simioni, Carolina, Martelli, Alberto M., Zauli, Giorgio, Ultimo, Simona, McCubrey, James A., Gonelli, Arianna, Marisi, Giorgia, Ulivi, Paola, Capitani, Silvano, Neri, Luca M.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342446/
https://ncbi.nlm.nih.gov/pubmed/27494886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10984
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars